Genmab — Oktober 2020
-
PRAC agenda: 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan
Applicant: Amgen Europe B.V.Scope: Extension of existing indication to include combination of Kyprolis (carfilzomib) with
daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the
SmPC are updated. The package leaflet is updated in accordance
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP -
Professor ærgrer sig over Medicinrådets afvisning af Dar MPV https://haematologisktidsskrift.dk/2-uncategorised/768-professor-aergrer-sig-over-medicinradets-afvisning-af-dar-mpv.html
-
Ses vi kl. 17? https://event.webinarjam.com/register/8/rp8nvfw
-
-
New trial - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies https://www.clinicaltrials.gov/ct2/show/NCT04606381?term=rHuPH20&lupd_s=10%2F27%2F2020&draw=2&rank=1
-
https://twitter.com/wattwurm73/status/1321464818776375296?s=21 HALOs teknologi anvendes også til Amivantamab sc!
-
Regarding the new Amivantamab: Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC).
-
-
Amivantamab har potentiale til at blive stort...
-
God morgen.
-
Q&A d. 27. nov. kl. 16.
-
Aktier/tendens: Vestas og DSV i fokus i nervøst marked: https://www.proinvestor.com/investornyt/669096/aktier-tendens-vestas-og-dsv-i-fokus-i-nervost-marked
-
Daratumumab efficacy in extramedullary orbital myeloma https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.3458
-
AMGEN: KYPROLIS
(carfilzomib) sales decreased 2% year-over-year driven by volume declines, as fewer new patients began treatment due to COVID-19. Early indications point to a strong launch of the new once-weekly KYPROLIS and DARZALEX (daratumumab) combination regimen that was approved by the U.S. Food and Drug Administration (FDA) in August. -
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1832672
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind